This round of adjustment to the National Essential Medicines List is aimed at reinforcing a dual focus on clinical necessity and innovative value. The selection and revision of the National Essential Medicines List follow the functional positioning of "highlighting essentials, meeting prevention and treatment needs, ensuring supply, prioritizing use, guaranteeing quality, and reducing financial burden." The process adheres to the principles of giving equal emphasis to traditional Chinese medicine and Western medicine, promoting the combined use of both, and prioritizing clinically preferred drugs. It also takes into comprehensive consideration factors such as China's basic medical and health service needs, the level of basic medical security, and drug supply assurance, in order to adjust the varieties and quantities of essential medicines.
The updated and revised edition of the National Essential Medicines List places particular emphasis on pediatric medication, focusing on common childhood diseases and expanding the range of children-appropriate drug varieties. Among the newly added drugs in this adjustment, 31 varieties are suitable for children, including 5 pediatric-specific drugs, further improving the accessibility of medicines for children. The new edition also prioritizes the addition of dosage forms and specifications suitable for children, such as granules, oral solutions, and suspensions, effectively addressing the long-standing pain point of "relying on breaking tablets for dosing and guessing for dosage" in pediatric medication.
Since its market launch, Xiao'er Chiqiao Qingre Granules (Tonpei) has been included in the National Reimbursement Drug List, owing to its unique clinical value and pediatric-specific dosage form. Over the years, it has undergone rigorous evidence-based medical validation and pharmacoeconomic evaluation, earning widespread recognition from municipal and county-level hospitals as well as primary healthcare institutions, and achieving considerable market coverage. With its inclusion in the National Essential Medicines List, Tonpei not only enhances drug accessibility but also further benefits a broader patient population.
JumpCan Pharmaceutical has always adhered to a patient-centered approach and actively fulfilled its social responsibilities as a listed pharmaceutical company. The company has continuously promoted the inclusion of products with high clinical demand and significant therapeutic value into both the National Medical Insurance Catalog and the National Essential Medicines List. The inclusion of Xiao'er Chiqiao Qingre Granules (Tonpei) in the National Essential Medicines List (2026 Edition) is not only a vivid practice of the company's commitment to social responsibility but also a microcosm of its efforts to benefit patients. Going forward, the company will further promote the availability of Tonpei in more primary healthcare institutions, ensure the basic medication needs of the public, reduce the medication burden on patients, and contribute to the high-quality development of China's healthcare sector.